Few autoimmune competitors even come close to commercial stalwarts Humira, Enbrel and Remicade. But as a host of high-science treatments emerge seeking to threaten their reign, an old-fashioned and heretofore illicit drug could beckon patients to look beyond traditional medicines for rheumatology relief. Joe Dysart surveys the sector
With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on a flurry of innovative biotech-developed assets. Noah Pines charts the rarefied air of the respiratory space
The launch front in this category is relatively calm—for now. A movement is brewing to unseat the top diabetes drug, a long-acting insulin, as faster-acting products emerge. Joe Dysart on the intrigue in the metabolic pipeline
"New and improved" has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends
Despite having the brightest data set of all the oral anticoagulants, the newest one is off to a rocky start. DTC advertising and medical education are under way, but it may take more to revive this launch.
In MS, a crop of orals has joined the older established therapies, yielding new options—and fierce competition. One thing they can all agree on: there's been a transformation of the treatment landscape in just the last three years. Noah Pines reports
While public health agencies see eye-to-eye with industry on the need to inoculate, vaccination rates among some patient groups remain stubbornly low. Noah Pines on what this means for drug makers, and other areas where industry is rolling up its collective sleeves in an effort to get patients to roll up theirs
Companies in this space are expanding beyond reproductive health into areas like menopause and osteoporosis. To succeed, they'll need to re-energize their physician and patient base. Noah Pines reports
Noah Pines on the race to market cancer drugs that harness the PD-1 pathway, other standouts in the onolcolgy pipeline, and what's already making waves in the market
Science is yielding all-oral therapies that can cure hepatitis C in three months, without injected interferon. But there are potential headwinds. Noah Pines sorts out the leaders in hep. C and the rest of the pipeline
Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from needle-based therapies
As specialty drugs enter the respiratory market, alongside successors to current blockbusters, Noah Pines looks at how big pharma aspires to sustain sales, and how the new entrants are making inroads
With the impending US approval of their oral blood thinner, this could be a big year for Bristol-Myers Squibb. But the other two warfarin replacements will continue to play important roles. Noah Pines sets the scene
The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at once. Noah Pines reports
Companies are looking carefully at the rare disease area now. But there's a steep curve, as firms in this burgeoning space face a host of unique challenges
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.